Endocrine Society, July 12-15

The annual meeting of the Endocrine Society (ENDO 2025) was held from July 12 to 15 in San Francisco, attracting more than 7,000 participants, including clinicians, academicians, allied health professionals, and others interested in endocrine and metabolic disorders. The conference highlighted recent advances in the diagnosis and management of obesity, endocrine disorders, diabetes, and growth hormone and thyroid diseases.In one presentation, Jennifer Wyckoff, M.D., of the University of Michigan in Ann Arbor, and colleagues presented a guideline recommending that all individuals with diabetes who have the possibility of becoming pregnant be asked a screening question about pregnancy intention at every reproductive, diabetes, and primary care visit, as well as at every urgent care/emergency room visit when clinically appropriate.The joint guideline was developed by the Endocrine Society and the European Society of Endocrinology on preexisting diabetes and pregnancy. The guideline includes 10 recommendations across preconception planning, advances in diabetes technology, delivery timing, medications, and diet. These recommendations were developed using GRADE methodology.The authors highlighted the use of contraception when pregnancy is not desired among individuals with diabetes mellitus who have the possibility of becoming pregnant. In addition, the experts suggested discontinuation of glucagon-like peptide 1 receptor agonists before conception rather than discontinuation between the start of pregnancy and the end of the first trimester. In pregnant individuals with preexisting diabetes mellitus already taking insulin, the authors suggested against the routine addition of metformin. The authors also provided guidance on diet, medications, and use of continuous glucose monitors and insulin pump systems among patients with type 1 or type 2 diabetes."An important point is that all of these recommendations are conditional recommendations, as the data available on which to base recommendations was of low quality, precluding the ability to make strong recommendations. This guideline highlights the importance of implementing preconception counseling and the need for implementation science and health care policy in this area," Wyckoff said. "The guideline also explores the benefits of and the knowledge gaps in the use of diabetes technology in pregnancy. It also underscores the need for providers with expertise in diabetes and pregnancy. Key knowledge gaps exist in the areas of nutrition in diabetes and pregnancy and timing of labor and delivery."Press ReleaseIn another study, Emily N. Hilz, Ph.D., of the University of Texas in Austin, and colleagues found that developmental exposure to endocrine-disrupting chemicals (EDCs) can alter brain pathways that regulate food reward and appetite, leading to long-lasting changes in eating behavior and food preferences.The authors evaluated how early-life exposure to EDCs affects food preferences and reward-related brain function later in life.Using a rat model, the researchers found that developmental exposure to a low-dose mixture of EDCs found commonly in the environment increased consumption of sugary and fatty foods in adulthood, with notable sex differences in behavioral outcomes. Females exposed early in life showed a strong preference for high-fat food and gained more weight, while males had a temporary preference for sucrose and exhibited reduced testosterone levels. Gene expression analyses revealed changes to brain regions involved in reward and feeding behavior, which were predictive of the observed eating patterns."These findings suggest a potential link between early-life chemical exposures and increased risk for obesity," Hilz said. "While this is an animal study, the results highlight the importance of minimizing exposure to endocrine-disrupting chemicals during pregnancy and early childhood. Increased awareness among clinicians and patients could support public health efforts aimed at reducing exposure to these chemicals as a potential strategy to help prevent diet-related metabolic disorders -- such as obesity -- later in life."Press ReleaseFaizan Ahmed, M.D., of the Hackensack Meridian Jersey Shore University Medical Center in Neptune City, New Jersey, and colleagues found that obesity-associated cancer mortality is rapidly increasing in the United States, and this trend reflects not only rising obesity rates but also delayed access to screening and care in certain populations.The authors analyzed more than 33,000 deaths due to obesity-associated cancers in the United States between 1999 and 2020 using the CDC WONDER database and found that the age-adjusted mortality rate (AAMR) more than tripled during this period, rising from 3.73 to 13.52 per million. The steepest increase occurred between 2018 and 2020. Women and Hispanic individuals experienced high average annual percent changes. Adults aged 65 years and older and residents in the Midwest showed the highest AAMRs."These findings highlight the need to reframe obesity from a lifestyle concern to a cancer prevention priority," Ahmed said. "Clinicians should incorporate obesity screening and management more proactively in routine visits, counsel patients on cancer risks associated with obesity, and advocate for equitable access to cancer screening, especially in high-risk and underserved populations."Press ReleaseENDO: Guidelines Developed for Pregnancy Care in Preexisting DiabetesFRIDAY, July 18, 2025 (HealthDay News) -- In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy care in individuals with preexisting diabetes mellitus. The guidelines were published online July 14 in the Journal of Clinical Endocrinology & Metabolism to coincide with presentation at ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.Read Full TextENDO: AI Model Integrated Into Retina Tracker IDs Diabetic RetinopathyFRIDAY, July 18, 2025 (HealthDay News) -- An artificial intelligence model integrated into a retina tracker for diabetic retinopathy can achieve high accuracy while being resource-efficient, according to a study presented at ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.Read Full TextENDO: Primary Aldosteronism Screening Recommended for All With HypertensionFRIDAY, July 18, 2025 (HealthDay News) -- All individuals with hypertension should be screened for primary aldosteronism, according to a clinical practice guideline issued by the Endocrine Society and published online July 14 in the Journal of Clinical Endocrinology & Metabolism. The guideline was published to coincide with ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.Read Full TextENDO: Older Age, Female Sex Tied to Greater Muscle Loss With SemaglutideTHURSDAY, July 17, 2025 (HealthDay News) -- Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is independently associated with less improvement in glucose homeostasis, according to a study presented at ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.Read Full TextENDO: Osteoporosis Treatment Benefits Elderly Patients With Fragility FractureTHURSDAY, July 17, 2025 (HealthDay News) -- Patients with osteoporosis who suffer a fragility fracture at age 80 years or older have better five-year outcomes if they receive treatment for osteoporosis, according to a study presented at ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.Read Full TextENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy UseTUESDAY, July 15, 2025 (HealthDay News) -- In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy is associated with superior weight loss outcomes, according to a study presented at ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.Read Full TextENDO: Sweeteners, Genetic Predisposition Independently Linked to Early PubertyTUESDAY, July 15, 2025 (HealthDay News) -- Sweetener consumption and genetic predisposition are independently associated with the risk for central precocious puberty, according to a study presented at ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.Read Full TextENDO: 1999 to 2020 Saw Significant Uptick in Obesity-Related Cancer DeathsMONDAY, July 14, 2025 (HealthDay News) -- From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.Read Full Text.Sign up for our weekly HealthDay newsletter

Endocrine Society, July 12-15

Related Stories